{"id":"NCT01324999","sponsor":"University of North Carolina, Chapel Hill","briefTitle":"Tadalafil for Sarcoidosis Associated Pulmonary Hypertension","officialTitle":"Tadalafil for Sarcoidosis Associated Pulmonary Hypertension","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-03","primaryCompletion":"2013-07","completion":"2013-10","firstPosted":"2011-03-29","resultsPosted":"2017-07-24","lastUpdate":"2017-07-24"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":[]}],"arms":[{"label":"Sarcoid Associated Pulm. Hypertension","type":"EXPERIMENTAL"}],"summary":"This study is designed to assess safety and efficacy of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension.\n\nHypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis","primaryOutcome":{"measure":"6 Minute Walk Distance","timeFrame":"Baseline, Week 8, Week 16, Week 24","effectByArm":[{"arm":"Tadalafil","deltaMin":419.1,"sd":170.1}],"pValues":[{"comp":"OG000","p":"0.68"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":17},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["28090299"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Headache","Joint pain","Herpes zoster","Influenza/pneumonia"]}}